Idiopathic Anaphylaxis

Paul A. Greenberger; Phillip Lieberman

doi:10.1016/j.jaip.2014.02.012

Idiopathic Anaphylaxis

Paul A. Greenberger, Phillip Lieberman^*

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Review article › peer-review

45 Scopus citations

Abstract

Idiopathic anaphylaxis is a perplexing problem that accounts for approximately 30% to 60% of cases of anaphylaxis in ambulatory adults and perhaps 10% of cases in children. Advances in our knowledge of idiopathic anaphylaxis have occurred over the past decade with the elucidation of mast cell activating disorders and the discovery of episodes of anaphylaxis caused by galactose-alpha-1,3-galactose. Most patients do well because fatalities can usually be prevented with proper therapy, and many individuals, for reasons not understood, undergo spontaneous remission.

Original language	English (US)
Pages (from-to)	243-250
Number of pages	8
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	2
Issue number	3
DOIs	https://doi.org/10.1016/j.jaip.2014.02.012
State	Published - May 2014

Keywords

Anaphylaxis
Galactose-alpha-1,3-galactose
Idiopathic anaphylaxis
Mast cell activating disorder
Mast cell activating syndrome

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2014.02.012

Cite this

@article{ba15878ea8234671be2659a8ede7f85b,

title = "Idiopathic Anaphylaxis",

abstract = "Idiopathic anaphylaxis is a perplexing problem that accounts for approximately 30% to 60% of cases of anaphylaxis in ambulatory adults and perhaps 10% of cases in children. Advances in our knowledge of idiopathic anaphylaxis have occurred over the past decade with the elucidation of mast cell activating disorders and the discovery of episodes of anaphylaxis caused by galactose-alpha-1,3-galactose. Most patients do well because fatalities can usually be prevented with proper therapy, and many individuals, for reasons not understood, undergo spontaneous remission.",

keywords = "Anaphylaxis, Galactose-alpha-1,3-galactose, Idiopathic anaphylaxis, Mast cell activating disorder, Mast cell activating syndrome",

author = "Greenberger, {Paul A.} and Phillip Lieberman",

year = "2014",

month = may,

doi = "10.1016/j.jaip.2014.02.012",

language = "English (US)",

volume = "2",

pages = "243--250",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Idiopathic Anaphylaxis

AU - Greenberger, Paul A.

AU - Lieberman, Phillip

PY - 2014/5

Y1 - 2014/5

N2 - Idiopathic anaphylaxis is a perplexing problem that accounts for approximately 30% to 60% of cases of anaphylaxis in ambulatory adults and perhaps 10% of cases in children. Advances in our knowledge of idiopathic anaphylaxis have occurred over the past decade with the elucidation of mast cell activating disorders and the discovery of episodes of anaphylaxis caused by galactose-alpha-1,3-galactose. Most patients do well because fatalities can usually be prevented with proper therapy, and many individuals, for reasons not understood, undergo spontaneous remission.

AB - Idiopathic anaphylaxis is a perplexing problem that accounts for approximately 30% to 60% of cases of anaphylaxis in ambulatory adults and perhaps 10% of cases in children. Advances in our knowledge of idiopathic anaphylaxis have occurred over the past decade with the elucidation of mast cell activating disorders and the discovery of episodes of anaphylaxis caused by galactose-alpha-1,3-galactose. Most patients do well because fatalities can usually be prevented with proper therapy, and many individuals, for reasons not understood, undergo spontaneous remission.

KW - Anaphylaxis

KW - Galactose-alpha-1,3-galactose

KW - Idiopathic anaphylaxis

KW - Mast cell activating disorder

KW - Mast cell activating syndrome

UR - http://www.scopus.com/inward/record.url?scp=84899964976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899964976&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2014.02.012

DO - 10.1016/j.jaip.2014.02.012

M3 - Review article

C2 - 24811012

AN - SCOPUS:84899964976

SN - 2213-2198

VL - 2

SP - 243

EP - 250

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 3

ER -

Idiopathic Anaphylaxis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this